Merck, Moderna Melanoma Vaccine Study Succeeds

Summary

Madison Muller discusses positive late-stage trial results from Merck and Moderna's personalized mRNA melanoma vaccine, which significantly reduced melanoma recurrence. The data lifted Moderna shares as investors see a post-COVID revenue opportunity, with regulatory approval possible next year. She also notes the potential to extend mRNA cancer vaccines to other tumors and vaccine hesitancy as a key consideration.

• Merck and Moderna reported positive late-stage data for a personalized mRNA melanoma vaccine.
• The trial showed significant reduction in melanoma recurrence.
• Moderna shares moved significantly on the news.
• The success is seen as validating mRNA flexibility beyond COVID and potentially across other cancers.
• The vaccine could reach market as soon as next year pending regulatory approval.
• Vaccine hesitancy and misinformation may affect uptake of mRNA cancer vaccines.